Narjust Florez, MD, FASCO (@NarjustFlorezMD) ranks #11 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 32 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: LIBRETTO-432, HARMONi-6, CROWN. CMS Open Payments lists $44,684 in 2025 general payments.
At a Glance
- 5 posts naming a trial in 2026
- 4 trials discussed by name
- Lung Cancer: US #11, Global #24 · 32 physicians engaged
- CMS Open Payments lists $44,684 in 2025 general payments.
This Month
What Narjust Florez, MD, FASCO has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Narjust Florez, MD, FASCO
Physicians who reposted Narjust Florez, MD, FASCO’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #11 | #24 | 32 | 40 | Full ranking |
What Colleagues Are Saying About Narjust Florez, MD, FASCO
2026 posts by fellow physicians that mention @NarjustFlorezMD, quoted word for word.
🔥 #WCLC26 Closing Lunch & Game Show! 🥇 Congratulations ▶️ 💊 Med Onc Team 🥇 Congratulations ▶️ "SMC (Samsung Medical Center) CRC" Team 🥉 Well Done No. 3 in Audience ▶️ Team "Hidehito Horinouchi" @NarjustFlorezMD @MaryPasquinelli @HHorinouchi (Didn't really get how it worked and accidentally made the team name just my own name... lol 🤣) #LCSM @IASLC @OncoAlert
So happy to see my friend Dr. @NarjustFlorezMD honored by Dr. @Tony_Calles and @tactics_md at an #ESMO26 reception full of close friends. https://t.co/4cVswXcQki
Fantastic event w/ @OncBrothers summarizing the major updates from #ASCO26! 🩺🔥 Brilliant insights from an all-star panel on #lungcancer featuring @StephenVLiu, @NarjustFlorezMD, & @RManochakian. Caught up w/ @RManochakian to discuss exciting progress in small cell lung cancer! https://t.co/xYCnaDnsBS
Really enjoyed this wonderful opportunity to discuss EVOKE-03/KN D46 data presented at the Presidential Symposium 1 of #WCLC26 with dear friends @StephenVLiu and @NarjustFlorezMD @IASLC Link🖇️ below:👇 https://t.co/JLVgL0ksLe
Always great catching up with @NarjustFlorezMD ! 😊 Every conversation is filled with insights-not only about the latest developments in lung cancer, but also thoughtful career advice and mentorship. 😃 #ASCO26 #LungCancer #Oncology https://t.co/hyuyxeNRmH
📣 #ESMO26 | HER-LUNG UK Proud to present our research on the experiences and unmet needs of younger women with lung cancer in 🇬🇧 Building on these findings, HER-ALERT aims to improve earlier recognition of lung cancer in younger women who have never smoked. Grateful to the @Roy_Castle_Lung for funding HER-LUNG UK and supporting this important research. Thanks to co-investigators @Yvonne_Diaz_ @NarjustFlorezMD Dr Florien Boele and @KathrynBanfill Dr Gordon and all the patients and caregivers who partecipated #ESMO26 #HERLUNG #HERALERT #LungCancer #HYMS @HullYorkMed @myESMO
Trials Narjust Florez, MD, FASCO Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| LIBRETTO-432 | 2 | #10 of 53 | Jun 2, 2026 |
| HARMONi-6 | 1 | #36 of 74 | May 31, 2026 |
| CROWN | 1 | #21 of 36 | May 30, 2026 |
| ADAURA | 1 | #39 of 41 | Apr 11, 2026 |
Narjust Florez, MD, FASCO on LIBRETTO-432
RET fusion–positive NSCLC just got its adjuvant targeted therapy LIBRETTO-432 is published in NEJM and the data are practice-changing. 🎯 Watch our clinical perspective below #ASCO26 Full publication: https://t.co/6YOeUhFO3n @RETpositive @YoungLungCancer @OncogeneCancer https://t.co/srjWZymr1p
🚨 PRACTICE CHANGING DATA at #ASCO26 🚨 LIBRETTO-432 Adjuvant selpercatinib vs placebo: ✅ HR 0.172 (p=0.0003) ✅ 24-mo EFS: 91.5% vs 61.1% ✅ Consistent across ALL subgroups This is why we TEST EVERY patient. Every. Single. One. 🧬 https://t.co/8gxj3UduwK
Narjust Florez, MD, FASCO on HARMONi-6
OUTRAGEOUS! From HARMONi-6 - 494 (93%) of patients were male and 38 (7%) of patients were female! Only 7%!! Despite SCC prevalence (26-40% in Asian women), women DESERVED to be included. https://t.co/rDNvoO1oOH #ASCO26 @OncoAlert https://t.co/AOgHdHHGma
Narjust Florez, MD, FASCO on CROWN
Day 1 of #ASCO2026 EGFR EXON20: New frontline EGFR exon 20 insertion data with encouraging efficacy signals in this historically difficult-to-treat population. CROWN: The 7-year update confirmed the durability of lorlatinib in ALK+ NSCLC, with mPFS still not reached & sustained https://t.co/IPlRVWMdjL
Narjust Florez, MD, FASCO on ADAURA
From EGFR to ALK to RET, adjuvant therapy in lung cancer is evolving fast. ADAURA, ALINA, and LIBRETTO-432 are redefining what “curative intent” can look like after surgery. The question is no longer if we should treat, but who, when, and how long. #TexasLung26 https://t.co/tYjwAxU3LA
Narjust Florez, MD, FASCO’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
How meaningful is “practice-changing” data if patients still cannot access the drug? Sunvozertinib has shown promising activity in EGFR exon20ins NSCLC, yet access remains the real endpoint that matters. A drug approval means little if, patients still cannot receive it. Innovation is not just generating data, it is delivering therapies to the people who need them #ASCO26
It’s time! To bring Lorlatinib to early stage ALK+ lung cancer #ASCO26 @pfizer @ALKPositiveinc @ALKpositiveINT https://t.co/CI5s39cGJK
Not all KRAS G12C inhibitors are equal. Once approved, divarasib could be our preferred option after first line, and the real question is how quickly we move it to the first line. Cautiously optimistic, as most control patients received sotorasib. #ESMO26 #lcsm #KRAS https://t.co/ku1dkDjieA
My joy and pride - the community that I once created so nobody will feel as isolated as once did. At our yearly lunch at #ASCO26 https://t.co/O98LWKpeCS
As we navigate the excitement, data, and breakthroughs at #ASCO26, let’s not forget why we’re here: our patients. Every abstract, every discussion, every collaboration matters only if it helps us improve their lives. Nothing is more important. ❤️ #Oncology #CancerCare
Industry Payments
CMS Open Payments · 2025 general payments
$44,684 across 47 payments